NovoCure Ltd. (NVCR), a leading oncology treatment company, saw its stock price plummet by 8.38% in the pre-market trading session on Thursday, following the release of its mixed fourth-quarter 2024 earnings report.
While the company reported a 21% year-over-year increase in revenue, reaching $161.3 million and matching analyst expectations, its profitability took a hit due to higher expenses. NovoCure reported a wider net loss of $0.61 per diluted share for the quarter, significantly worse than the expected loss of $0.34 per share.
The primary factor contributing to the larger-than-anticipated loss was a substantial 84% surge in general and administrative expenses compared to the prior year. This increase was largely driven by a $36.1 million one-time stock-based compensation charge related to FDA approvals for the company's Tumor Treating Fields (TTFields) therapy.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。